Sue Dillon is a co-founder of Aro Biotherapeutics, focused on Centyrins, a unique protein platform designed to enable optimized delivery of multiple drug payloads including nucleic acid and genetic therapeutics for diseases with high unmet need.
Previously, from 2001 through 2017 Sue held multiple leadership roles at Centocor and Janssen Research & Development, a division of Johnson & Johnson Pharmaceuticals. In 2009, Sue was appointed Global Therapeutic Area Head for immunology for Janssen, Research and Development. In this role, Sue had end-to-end responsibility for immunology small and large molecule drug discovery, biomarkers, translational medicine, and clinical development of a series of blockbuster products for autoimmune diseases, including REMICADE® (infliximab), SIMPONI® (golimumab), STELARA® (ustekinumab), and TREMFYA® (guselkumab), a first in class anti-IL-23 antibody approved in 2017.
Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, Philadelphia and completed an NIH-sponsored postdoctoral fellowship in Immunology at Duke University. Sue has published over 50 scientific articles, and is inventor on six issued patents.
In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University and in 2013 Sue was selected by FierceBiotech as one of the “Top Women in Biotech.” Sue is on the Boards of the Wistar Institute and